Molecular Partners AG — Investor Relations & Filings

Molecular Partners AG is a clinical-stage biopharmaceutical company pioneering the design and development of a novel class of protein therapeutics known as DARPin® therapies. DARPins (Designed Ankyrin Repeat Proteins) are a proprietary class of small, custom-built proteins engineered to bind to specific disease targets with high potency and specificity. The company leverages its platform to create multi-specific drug candidates capable of engaging multiple targets or pathways simultaneously. The development pipeline is primarily focused on advancing innovative treatments in oncology, with clinical programs targeting serious diseases such as acute myeloid leukemia (AML). The company's approach aims to address complex medical challenges by utilizing the unique properties of its engineered protein platform.